TEVOGEN BIO HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1 USD | +0.96% |
|
+3.09% | -91.02% |
| Apr. 26 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
| Apr. 26 | Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | - | - |
| Enterprise Value (EV) 1 | - | - |
| P/E ratio | -11.8 x | -4.56 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | -7.53 x | -2.92 x |
| Nbr of stocks (in thousands) | - | - |
| Reference price 2 | 10.33 | 11.13 |
| Announcement Date | 1/10/24 | 4/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA 1 | -4.609 | -13.63 | -8.68 |
| EBIT 1 | -4.618 | -13.72 | -8.843 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -15.6 | -22.04 | -60.48 |
| Net income 1 | -15.6 | -22.04 | -60.48 |
| Net margin | - | - | - |
| EPS 2 | -0.6219 | -0.8728 | -2.443 |
| Free Cash Flow | - | -4.115 | -3.521 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 1/10/24 | 1/10/24 | 4/29/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | 16.4 | 34.5 | 94.4 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | -3.549 x | -2.532 x | -10.87 x |
| Free Cash Flow | - | -4.11 | -3.52 |
| ROE (net income / shareholders' equity) | - | 87.4% | 94.2% |
| ROA (Net income/ Total Assets) | - | -111% | -83.5% |
| Assets 1 | - | 19.78 | 72.46 |
| Book Value Per Share 2 | -0.6600 | -1.370 | -3.820 |
| Cash Flow per Share 2 | 0.2800 | 0.2200 | 0.0400 |
| Capex 1 | 0.11 | 0.48 | 0.13 |
| Capex / Sales | - | - | - |
| Announcement Date | 1/10/24 | 1/10/24 | 4/29/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -91.02% | 165M | |
| +22.56% | 46.71B | |
| +48.83% | 41.8B | |
| -1.51% | 41.52B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B | |
| +26.45% | 11.98B |
- Stock Market
- Equities
- TVGN Stock
- Financials Tevogen Bio Holdings Inc.